Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 15, 2016 - Issue 5
Submit an article Journal homepage
1,022
Views
25
CrossRef citations to date
0
Altmetric
Meta-Analysis

Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials

Britta GallingThe Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA
,
Alexandra RoldánDepartment of Psychiatry, Institut d’Investigació Biomédica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
,
Liz RietschelUniversity Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland
,
Katsuhiko HagiThe Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA;Sumitomo Dainippon Pharma Co., Ltd., Medical Affairs, Tokyo, Japan
,
Frozan WalyzadaThe Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA
,
Wei ZhengDepartment of Psychiatry, Guangzhou Brain Hospital (Guangzhou Huiai Hospital), Affilated Hospital of Guangzhou Medical University, Guangzhou, China
,
Xiao-Lan CaoDepartment of Psychiatry, Chinese University of Hong Kong, Hong Kong, China
,
Yu-Tao XiangUnit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao, China
,
John M. KaneThe Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA;Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA;The Feinstein Institute for Medical Research, Manhasset, NY, USA;Albert Einstein College of Medicine, Bronx, NY, USA
&
Christoph U. CorrellThe Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA;Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA;The Feinstein Institute for Medical Research, Manhasset, NY, USA;Albert Einstein College of Medicine, Bronx, NY, USACorrespondence[email protected]
 show all
Pages 591-612 | Received 19 Jan 2016, Accepted 24 Feb 2016, Published online: 07 Apr 2016

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Justin Faden, Natasha Kiryankova-Dalseth, Ruby Barghini & Leslie Citrome. (2021) Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. Expert Opinion on Pharmacotherapy 22:5, pages 635-646.
Read now
Justin Faden & Leslie Citrome. (2019) Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment. Expert Opinion on Pharmacotherapy 20:1, pages 11-24.
Read now
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll & André F Carvalho. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management 13, pages 757-777.
Read now

Articles from other publishers (22)

Emily Eyles, Ruta Margelyte, Hannah B Edwards, Paul A Moran, David S Kessler, Simon J C Davies, Blanca Bolea-Alamañac, Maria Theresa Redaniel & Sarah A Sullivan. (2023) Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink. Schizophrenia Bulletin.
Crossref
Xuebing Liu, Xianzhi Sun, Lu Li, Kuan Zeng, Yi Li, Yujun Gao & Jun Ma. (2023) Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: A retrospective clinical study. Frontiers in Psychiatry 14.
Crossref
Hiroyoshi Takeuchi. (2022) The promise and pitfalls of antipsychotic co-initiation in schizophrenia. The Lancet Psychiatry 9:4, pages 262-263.
Crossref
Srinivasan Tirupati. (2021) The risk for Torsades de Pointes and polypharmacy in schizophrenia. Schizophrenia Research 228, pages 239-240.
Crossref
Matthias J. Müller & Otto Benkert. 2021. Kompendium der Psychiatrischen Pharmakotherapie. Kompendium der Psychiatrischen Pharmakotherapie 255 449 .
Sharea Ijaz, Blanca Bolea, Simon Davies, Jelena Savović, Alison Richards, Sarah Sullivan & Paul Moran. (2020) Antipsychotic Polypharmacy and Metabolic Syndrome in Schizophrenia: A Review of Systematic Reviews. FOCUS 18:4, pages 482-492.
Crossref
Shih-Ku Lin. (2020) Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. International Journal of Neuropsychopharmacology 23:2, pages 125-131.
Crossref
Takuro Sugai, Yutaro Suzuki, Manabu Yamazaki, Norio Sugawara, Norio Yasui-Furukori, Kazutaka Shimoda, Takao Mori, Yuji Ozeki, Hiroshi Matsuda, Kurefu Okamoto, Toyoaki Sagae & Toshiyuki Someya. (2020) Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy. Journal of Clinical Psychopharmacology 40:1, pages 14-17.
Crossref
Ching-Hua Lin, Fu-Chiang Wang, Yu-Hui Huang, Shih-Chi Lin & Chao-Chan Kuo. (2019) Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis. CNS Spectrums 24:6, pages 632-633.
Crossref
Jari Tiihonen, Heidi Taipale, Juha Mehtälä, Pia Vattulainen, Christoph U. CorrellAntti Tanskanen. (2019) Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry 76:5, pages 499.
Crossref
Wei Zheng, Xiao-Min Zhu, Qing-E Zhang, Xin-Hu Yang, Dong-Bin Cai, Lu Li, Xian-Bin Li, Chee H. Ng, Gabor S. Ungvari, Yu-Ping Ning & Yu-Tao Xiang. (2019) Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophrenia Research 206, pages 13-20.
Crossref
Tak Youn, Seong Hoon Jeong, Yong Sik Kim & In Won Chung. (2019) Long-term clinical efficacy of maintenance electroconvulsive therapy in patients with treatment-resistant schizophrenia on clozapine. Psychiatry Research 273, pages 759-766.
Crossref
M. J. Müller & O. Benkert. 2019. Kompendium der Psychiatrischen Pharmakotherapie. Kompendium der Psychiatrischen Pharmakotherapie 284 504 .
Sharea Ijaz, Blanca Bolea, Simon Davies, Jelena Savović, Alison Richards, Sarah Sullivan & Paul Moran. (2018) Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 18:1.
Crossref
Kazunori Suzuki, Akina Harada, Hirobumi Suzuki, Clizia Capuani, Annarosa Ugolini, Mauro Corsi & Haruhide Kimura. (2018) Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents. Pharmacology Research & Perspectives 6:1, pages e00372.
Crossref
Wei Zheng, Xiao-Hong Li, Dong-Bin Cai, Xin-Hu Yang, Gabor S. Ungvari, Chee H. Ng, Yu-Ping Ning & Yu-Tao Xiang. (2018) Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. European Neuropsychopharmacology 28:1, pages 149-158.
Crossref
Drigissa Ilies, Anne-Sophie Huet, Eric Lacourse, Geneviève Roy, Emmanuel Stip & Leila Ben Amor. (2017) Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study. The Canadian Journal of Psychiatry 62:12, pages 827-836.
Crossref
Ching-Hua Lin, Fu-Chiang Wang, Shih-Chi Lin, Yu-Hui Huang & Cheng-Chung Chen. (2017) A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. Schizophrenia Research 185, pages 80-87.
Crossref
Athan Spiros, Patrick Roberts & Hugo Geerts. (2017) Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop. European Neuropsychopharmacology 27:2, pages 107-119.
Crossref
Alex Yow & Mahesh B Jayaram. (2017) Non-clozapine antipsychotic combinations for treatment-resistant schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Jean-Daniel Carrier, Lucie Blais, Alan Cohen, Josiane Courteau, Pasquale Roberge, Annie Larouche, Sylvain Grignon, Marie-Josée Fleury, Alain Lesage, Marie-France Demers, Marc-André Roy, André Delorme & Alain Vanasse. (2017) Amorcer un traitement antipsychotique en schizophrénie : la situation au Québec de 1998 à 2006. Santé mentale au Québec 42:1, pages 85-103.
Crossref
Maria Pontillo, Franco De Crescenzo, Stefano Vicari, Maria Laura Pucciarini, Roberto Averna, Ornella Santonastaso & Marco Armando. (2016) Cognitive behavioural therapy for auditory hallucinations in schizophrenia: A review. World Journal of Psychiatry 6:3, pages 372.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.